2025 in review, and come on 2026!
With 2025 finished, it is worth reflecting on our contributions to evidence-based healthcare. This year, our excellent team completed a large number of projects. These included systematic reviews, cost-effectiveness analyses, health technology assessments (HTAs), and guideline development support which were commissioned by government agencies including NICE, charities, and industry partners.
We are excited to share our key outputs below, and to give a brief look-ahead for 2026 which promises exciting opportunities and as always a lot of evidence synthesising!
New partners
We are incredibly proud to have been chosen to support the British Heart Foundation (BHF) to develop a living clinical guideline for the prevention of cardiovascular disease (CVD). The project is now underway, with the next guideline development group (GDG) meeting scheduled to take place in March.
KSR has undertaken several systematic reviews for a range of pharmaceutical and medical device companies. In many cases, these are returning customers, highlighting the commitment of KSR to understand and meet the needs of the commissioners.
National Institute for Health and Care Excellence (NICE)
Kleijnen Systematic Reviews Ltd is a “Centre of Excellence” for Technology Assessment Reviews (TARs), appointed by the National Institute for Health Research (NIHR).
In 2025, KSR contributed to a number of appraisal committee meetings and the following evidence reports have been published by NICE:
- Betula verrucosa for treating moderate to severe allergic rhinitis or conjunctivitis caused by tree pollen
- Digital platforms to support cardiac rehabilitation: early value assessment
- Guselkumab for previously treated moderately to severely active Crohn’s disease
- Linzagolix for treating symptoms of endometriosis
- Sebetralstat for treating acute attacks of hereditary angioedema in people aged 12 and over
- Vanzacaftor-tezacaftor-deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and over
The following projects are ongoing, with publication expected in 2026:
- Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer
- Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when an autologous stem cell transplant is suitable
- Encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer
- Pegcetacoplan for treating primary complement 3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis in people 12 years and over
- Remibrutinib for treating chronic spontaneous urticaria inadequately controlled by H1-antihistamines
- Sebetralstat for treating acute attacks of hereditary angioedema in people aged 12 and over
- Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (MA review of TA781)
- Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes
- Teprotumumab for treating thyroid eye disease
Come on 2026!
Looking toward 2026, KSR remains dedicated to delivering expertly researched systematic reviews, HTAs, and analyses that inform decisions at the highest level. Our work as part of the guideline development group for the BHF exemplifies our commitment to thorough science, and this work will continue into 2026 and include various KSR team members at different stages of the project. We are also looking forward to continuing working with our industry partners. Several cooperations have resulted in the preparation of manuscripts, watch this space to get an update on these publications.
Connect with us
Follow us for updates from the KSR team as we continue working on independent, evidence-based science in healthcare, and keep an eye on our website News section for regular updates on projects, thought pieces from our experts, and more!
